

Our ref: FOI 3576

10th February 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- **R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**
- **R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine)**
- **Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)**
- **R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)**
- **R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)**
- **R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)**
- **(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)**
- **R-GemOX (rituximab, gemcitabine and oxaliplatin)**
- **Axicabtagene ciloleucel**
- **Tisagenlecleucel**
- **Epcoritamab**
- **Loncastuximab tesirine**
- **Glofitamab**
- **Any other SACT**

- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- **Axicabtagene ciloleucel (Yescarta)**
- **Tisagenlecleucel**
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine)**
- **R-GemOX (rituximab, gemcitabine and oxaliplatin)**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **Glofitamab**
- **Any other treatments**

Q4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?

Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- **CAR-T Therapy (E.g. Axicabtagene ciloleucel)**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **Any other treatment**

Response:

There is no way to extract the data for patients diagnosed with Diffuse Large B Cell Lymphoma.

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. To obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient charts just to ascertain if



Southern Health
and Social Care Trust

information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Foi.Team@Southerntrust.hscni.net